We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Toxic Factor in Gluten Identified

By Biotechdaily staff writers
Posted on 08 Oct 2002
Researchers have identified a 33-amino acid peptide, a breakdown product of gluten, which apparently triggers the autoimmune response in the small intestine that characterizes the syndrome called celiac sprue. Their findings were published in the September 27, 2002, issue of Science.

In vitro and in vivo studies in rats and humans demonstrated that the peptide was stable toward breakdown by all gastric, pancreatic, and intestinal brush-border membrane proteases. The only proteolytic enzyme that was found to degrade the peptide was a bacterial prolyl endopeptidase.

The peptide reacted with tissue transglutaminase, the major autoantigen in celiac sprue, with substantially greater selectivity than known natural substrates of this extracellular enzyme. It was a potent inducer of gut-derived human T cell lines from 14 of 14 celiac sprue patients. The peptide was found in all gluten-containing grains, but was not present in grains that do not contain gluten.

The study presents, "a combined chemical-physiological-immunological answer to the question: why is gluten toxic to a person with celiac sprue?” said senior author Dr. Chaitan Khosla from Stanford University (Palo Alto, CA, USA). "If proven correct, the findings will lead to new insights into the causes of celiac sprue, and perhaps certain other types of autoimmune diseases.”

The researchers believe that the bacterial endopeptidases, which were effective in human tissue cultures as well as living rats, may result in a simple, oral supplement that would alleviate the harmful effects of gluten. This treatment approach would be similar to enzyme supplements taken orally by those unable to digest lactose.



Related Links:
Stanford University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Hematology Consumables
Bioblood Devices

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
08 Oct 2002  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
08 Oct 2002  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
08 Oct 2002  |   BioResearch